Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$1.56M+16.7%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$820K+43.9%
Alkermes logo
AlkermesALKS
$7.48M+15.7%
TRV
Trevi Therapeutics, Inc.TRVI
$318K+15.2%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$1.5M-16.7%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.58B+64.7%
Enterprise value$4.92B+86.4%
P/E18.3×-7.5×
P/S3.6×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemMarch 31, 2026December 31, 2025
Accounts payable and accrued expenses178250
Accrued litigation settlement expenses, current1442
Current portion of long-term debt—29
Operating lease liabilities, current910
Income taxes payable262
Total current liabilities779914
Long-term debt, less current portion486290
Accrued litigation settlement expenses, noncurrent4152

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s operating lease liabilities (current)?
Indivior Pharmaceuticals, Inc. (INDV) reported operating lease liabilities (current) of $9M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s operating lease liabilities (current) changed year-over-year?
Indivior Pharmaceuticals, Inc.'s operating lease liabilities (current) decreased by 18.2% year-over-year, from $11M to $9M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s operating lease liabilities (current)?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s operating lease liabilities (current) has grown at a 5.4% compound annual growth rate (CAGR), from $9M to $10M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Indivior Pharmaceuticals, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude